Hypertension is estimated to affect about 1.2 billion people globally, and would require a far larger commercial infrastructure to support an approved drug. Thus, Alnylam plans to co-commercialise zilebesiran only in the US market but takes Roche as a commercialisation partner in the rest of the world.
After years of prioritising oncology and immunology on cost of cardiology, Big pharma is renewing its investments in cardiology due to better stratification, thus smaller and real-world data supported clinical trails that significantly reduce costs. While Novartis bought Leqvio developer The Medicines Company, BMS took over heart failure specialist Myokardia, which got market authorisation for Camzyos. Other companies such as Amgen or Merck & Co are recently adapting its pipelines.